Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH ...

Metastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge, with low 5-year survival rates and limited durable respons ...

General and Administrative (G&A) Expenses. G&A expenses for the three months ended March 31, 2025 were $6.9 million compared to $5.1 million for the same period in 2024. The increase was primarily ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

The Manila Times is one of the leading national broadsheets in the Philippines. It is also one of the oldest, having been founded in 1898. PR Newswire ...

DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market ...

Gastric cancer, the fifth most common malignancy worldwide and the fifth most common cause of cancer-related death, is ...

A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21 ... study suggests estrogen-related receptors could be a key to repairing ...

The vitamin D receptor activator (VDRA ... patients treated with VDRAs might result from stimulation of fibroblast growth factor 23 (FGF-23) production by these agents. 6 VDRAs can be used ...

A pioneering research study details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works primarily by signaling the brain to ...